Decrease of ABCB1 protein expression and increase of G₁ phase arrest induced by oleanolic acid in human multidrug-resistant cancer cells

DIDI WANG¹, JINCAI WANG², JUAN ZHANG², XIN YI¹³, JINHUA PIAO¹, LI LI¹, JIANJIE WANG¹, PENGXIA ZHANG¹ and QIYANG HE²

¹Key Laboratory of Microecology-immune Regulatory Network and Related Diseases, School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154000; ²Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P.R. China

Received September 15, 2020; Accepted March 15, 2021

DOI: 10.3892/etm.2021.10167

Abstract. Oleanolic acid (OA) is a natural compound that can be found in a number of edible and medicinal plants and confers diverse biological actions. However, the direct target of OA in human tumor cells remains poorly understood, preventing its application in clinical and health settings. A previous study revealed that overexpression of caveolin-1 in human leukemia HL-60 cells can increase its sensitivity to OA. The present study aimed to investigate the effects of OA on the doxorubicin-resistant human breast cancer MCF-7 cell line (MCF-7/DOX), harringtonine-resistant human leukemia HL-60 cells (HL-60/HAR) and their corresponding parental cell lines. Western blotting was performed to measure protein expression levels, whilst Cell Counting Kit-8 (CCK-8) assays, cell cycle analysis (by flow cytometry) and apoptosis assays (with Annexin V/PI staining) were used to assess drug sensitivity. CCK-8 assay results suggested that MCF-7/DOX cells, which overexpress the caveolin-1 protein, have similar OA susceptibility to their parent line. In addition, sensitivity of MCF-7/DOX cells to OA was not augmented by knocking down caveolin-1 using RNA interference. HL-60/HAR cells exhibited a four-fold increased sensitivity to OA compared with that in their parental HL-60 cells according to CCK-8 assay. Both of the resistant cell lines exhibited higher numbers of cells at G₁ phase arrest compared with those in their parent lines, as measured via flow cytometry. Treatment of both MCF-7 cell lines with 100 µM OA for 48 h induced apoptosis, with increased effects observed in resistant cells. However, no PARP-1 or caspase-3 cleavage was observed, with some positive Annexin V staining found after HL-60/HAR cells were treated with OA, suggesting that cell death occurred via non-classical apoptosis or through other cell death pathways. It was found that OA was not a substrate of ATP-binding cassette subfamily B member 1 (ABCB1) in drug-resistant cells, as indicated by the accumulation of rhodamine 123 assessed using flow cytometry. However, protein expression of ABCB1 in both of the resistant cell lines was significantly decreased after treatment with OA in a concentration-dependent manner. Collectively, these results suggest that OA could reduce ABCB1 protein expression and induce G₁ phase arrest in multidrug-resistant cancer cells. These findings highlight the potential of OA for cancer therapy.

Introduction

Oleanolic acid (OA) is a bioactive triterpenoid that can exist in nature as a free acid in a number of edible and medicinal plants, including olives, sage Lantana camara and the privet Ligustrum lucidum (1). OA has been reported to exert antioxidant, antibacterial and antitumor effects on human cells (such as hepatocellular carcinoma and breast cancer cells) and has been applied in China as a drug for treating liver diseases for >20 years (2). Several signaling pathways have been documented to be regulated by OA, including 5’adenosine monophosphate-activated protein kinase, NF-κB and mTOR pathways (3-5). In addition, OA can induce apoptosis and autophagy in numerous types of tumor cells, such as hepatocellular carcinoma cells (1,6-9) and attenuate cisplatin-induced nephrotoxicity (10). Although previous studies have reported
that OA can arrest cell cycle progression at the G2 phase, such as in gallbladder cancer cells (1,11), it also blocks liver cancer HepG2 cells at the G1/M phase (7).

Multidrug resistance in tumors is one of the main causes of chemotherapy failure (12). Upregulation of transmembrane transporters in tumor cells, such as ATP-binding cassette subfamily B member 1 (ABCB1 or P-glycoprotein) and multidrug resistance-associated protein (MRP1 or ABCC1), mainly contribute to drug resistance, since these proteins pump antitumor agents out of the tumor cells (12-14). ABCB1 was primarily discovered as a mediator of multidrug resistance in breast cancer MCF-7 cells (12). It has been previously reported that OA can inhibit MRP1 function, but not ABCB1 function in drug-resistant sarcoma cells (15). However, a chemically modified OA derivative can target ABCB1 (16). To facilitate the clinical application of OA as a chemotherapeutic agent, it is necessary to characterize the actions of OA further in ABCB1-overexpressing tumor cells.

Molecules that directly mediate the actions of OA on tumor cells remain poorly understood. In a previous study, it was revealed that transfection of human acute myelogenous leukemia HL-60 cells with caveolin-1 (CAV-1) conferred increased susceptibility to OA (17), suggesting that CAV-1 may be a target for mediating the antitumor action of OA. In another study, which aimed to characterize the role of CAV-1 in the antitumor action of bleomycin (18), it was observed that CAV-1 was upregulated in the doxorubicin-resistant human breast cancer cell line MCF-7 (MCF-7/DOX). Therefore, the present study investigated whether OA can affect multidrug resistance in cancer cells via CAV-1. It also further determined the characteristics of drug resistance in cell lines after exposure to OA.

Materials and methods

Drugs and reagents. Harringtonine (HAR) and OA were purchased from the National Institute of Food and Drug Control (Beijing, China). Imatinib was obtained from Selleck Chemicals. Doxorubicin (DOX), vincristine (VCR), cis-diaminedichloroplatinum, dimethyl sulfoxide, propidium iodide (PI) and rhodamine 123 (Rho 123) were all acquired from Sigma-Aldrich, Merck KGaA. Cell Counting Kit-8 (CCK-8) was purchased from Bimake.com and the apoptotic Annexin V/PI kit was obtained from Beijing 4A Biotech Co., Ltd.

Cell lines and culture. The human leukemia HL-60 cell line was acquired from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. The HAR-resistant HL-60 cell line (HL-60/HAR) was established by Professor Q. He, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences (Beijing, China) (19). The human breast cancer MCF-7 and MCF-7/DOX cell lines were kindly provided by Dr Kenneth H Crown (National Institutes of Health, Baltimore, USA). The resistant cell lines were used in the experiments after the withdrawal of the resistance-inducing drugs for 4 weeks. Sensitive MCF-7 and MCF-7/DOX cells were cultured in RPMI-1640 medium (HyClone; Cytiva). Sensitive HL-60 and HL-60/HAR cells were maintained with Improved Minimum Essential Medium (HyClone; Cytiva). A total of 10% (v/v) FBS (PAN-Biotech GmbH) was supplemented to all media. All cell lines were cultured with 5% CO2 in a humidified atmosphere at 37°C.

Western blot analysis. Western blotting was performed as described previously (20). Cells (MCF-7, MCF-7/DOX, HL-60 and HL-60/HAR) were lysed with lysis buffer, which contained 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 1% Triton X-100 and protease inhibitors [Roche Diagnostics (Shanghai) Co., Ltd.]. The protein concentrations of the samples were determined using the Quick Start Bradford 1X Dye Reagent (cat. no. 500-0205; Bio-Rad Laboratories Inc.), according to the manufacturer’s protocol, and by measuring the absorbance at 590 nm with a microplate reader (Bio-Rad Laboratories, Inc.). The samples with 20 µg protein per lane were separated via SDS-PAGE on 7.5 or 12.5% gels and then transferred onto polyvinylidene fluoride membranes. The membrane was blocked with 5% BSA for 1 h at room temperature, incubated with primary antibodies for 12 h at 4°C, washed and then incubated with secondary antibodies at room temperature. The immunoreactive bands were visualized with the ECL Plus Western Blotting Detection System (Bio-Rad Laboratories, Inc.) and detected with an Amersham Imager 600 (GE Healthcare). The bands were quantified with ImageJ 1.46 software (National Institutes of Health). Antibodies against ABCB1 (cat. no. 12273, 1:1,000), CAV-1 (cat. no. 3238, 1:1,000), poly(ADP-ribose) polymerase 1 (PARP-1; cat. no. 9532, 1:2,000), caspase-3 (CASP-3, cat. no. 9662, 1:1,000) and cleaved caspase-3 (CASP-3-C, cat. no. 9664, 1:500) were acquired from Cell Signaling Technology, Inc. β-actin (cat. no. sc-47778, 1:100,000) and p53 (cat. no. sc-126, 1:2,000) antibodies were obtained from Santa Cruz Biotechnology, Inc. Horseradish peroxidase-conjugated goat anti-rabbit (cat. no. hs101-01, 1:1,000) and anti-mouse IgG (cat. no. hs201-01, 1:1,000) antibodies were acquired from Transgen Biotech Co., Ltd.

Detection of Rho 123 accumulation. Since Rho 123 is the substrate of ABCB1, its fluorescence intensity can be used as an indicator of the relative levels of ABCB1 (15,21). A total of 2x10⁴ cells from the 4 cell lines per well at the logarithmic growth phase were seeded into a six-well plate. After 24 h incubation at 37°C, the cells were exposed to different concentrations of OA (10, 20, 40, 80 and 100 µM) for 1 h at 37°C. Rho 123 (5 µg/ml) was then added to the culture medium and the plate was incubated for 1.5 h at 37°C. The total incubation time with OA was 2.5 h. The cells were then collected after centrifugation at 800 x g for 5 min at room temperature. The fluorescence intensity was detected using a BD FACSCalibur™ flow cytometer (BD Biosciences). The data were analyzed using CellQuest Pro software version 5.1 (BD Biosciences).

RNA interference. RNA interference was performed according to a previously described protocol (18). Small interfering (si)RNA against CAV-1 and scrambled siRNA were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.). The sequence of CAV-1 siRNA was 5'-UUUUCACUGCCUUC AAGUGUGGCCG-3', and the sequence of scrambled siRNA was 5'-AAGUUAGUUCGUCUGAAACGGUUC-3'. The
MCF-7/DOX cells were transfected with 100 pmol siRNA for 6 h using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The transfected cells were cultured in fresh culture medium for 18 h and then used for subsequent experiments.

**CCK-8 assay.** CCK-8 assay was performed by following a previously described protocol (20). A total of 3,000 cells from 4 the cell lines at the logarithmic growth phase was seeded into a 96-well plate and incubated for 24 h at 37°C. Cells were exposed to the drugs for 72 h at 37°C. The MCF-7 cells were treated with DOX (0.05, 0.1, 0.5 or 1, 5 µM), VCR (0.005, 0.01, 0.05, 0.1 or 0.2 µM), DDP (1, 5, 10, 20 or 50 µM) and OA (20, 40, 80, 100 or 120 µM) for 72 h at 37°C. The MCF-7/DOX cells were treated with DOX (1, 5, 10, 20 or 50 µM), VCR (0.5, 1, 2, 5 or 10 µM), DDP (0.5, 1, 5, 10 or 20 µM) and OA (20, 40, 80, 100 or 120 µM) for 72 h at 37°C. The HL-60 cells were treated with HAR (0.001, 0.005, 0.01, 0.05 or 0.1 µM), DOX (0.01, 0.05, 0.1, 0.2 or 0.5 µM), VCR (0.05, 0.1, 0.5, 1, 2 or 5 nM), imatinib (2, 5, 10, 20 or 50 µM) and OA (20, 40, 80, 100 or 120 µM) for 72 h at 37°C. The HL-60/HAR cells were treated with HAR (0.1, 0.5, 1, 5 or 10 µM), DOX (0.1, 0.5, 1, 5 or 10 µM), VCR (100, 200, 500, 1,000, 2,000 nM), imatinib (2, 5, 10, 20 or 50 µM) and OA (5, 10, 20 or 40 µM) for 72 h at 37°C. After co-incubation with the aforementioned drugs, 20 µl of CCK-8 per lane for 2 h at 37°C, the optical density (OD) values at 450 nm were measured using a microplate reader (Bio-Rad Laboratories, Inc.). The viability of the control group that did not receive OA treatment was set as 100%. The cell survival rates of resistant cells were calculated using the following equation: Viability (%)=(OD of the drug-treated groups-OD of background)/(OD of the control group-OD of background)×100%. The data were plotted with GraphPad Prism 5 (GraphPad Software, Inc.).

**Cell cycle analysis via flow cytometry.** The cells at the logarithmic growth phase were seeded into a six-well plate with a density of 2x10⁵ cells/well and incubated for 24 h at 37°C. After exposure to OA for 24 h at 37°C, the MCF-7 and MCF-7/DOX cells were digested and collected after centrifugation at 800 x g for 5 min at room temperature. HL-60 and HL-60/HAR cells were collected for centrifugation at 800 x g for 5 min at room temperature. The cells were then fixed with 70% (v/v) ethanol overnight at 4°C. Before the assay, the cells were washed twice with cold PBS and incubated with 100 µg/ml RNase A (Beijing Solarbio Science & Technology Co., Ltd.) for 30 min at 37°C. The cells from the 4 cell lines were stained with 50 µg/ml PI for 1 h in the dark at room temperature. Finally, the fluorescence intensities of the groups were measured using a BD FACSCalibur™ flow cytometer (BD Biosciences). The data were analyzed using ModFit LT software version 5.1 (Verity Software House, Inc.).

**Measurement of apoptotic cells using Annexin V/PI staining.** Cells (3x10⁵) at the logarithmic growth phase were seeded into a six-well plate and maintained for 24 h at 37°C. After exposure to various concentrations of OA (20, 40, 80 and 100 µM) for 48 h at 37°C, the cells were collected and washed twice with cold PBS. The cells (MCF-7, MCF-7/DOX, HL-60 and HL-60/HAR) were resuspended with binding buffer and stained with 5 µl Annexin V-FITC for 5 min at room temperature in the dark. After the addition of 2 µg/ml PI to the cell suspension for 15 min at room temperature, the fluorescence intensities were analyzed using a BD FACSCalibur™ flow cytometer (BD Biosciences). The data were processed with CellQuest Pro software version 5.1 (BD Biosciences).

**Statistical analysis.** Data are presented as the mean ± SD from three independent experiments. Statistical analysis was conducted using one-way ANOVA followed by Tukey's test using SPSS 19.0 (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Characterization of drug-resistant MCF-7/DOX and HL-60/HAR cells.** The viability of cells treated with the indicated antitumor drugs was determined using CCK-8 assay. The IC₅₀ values are summarized in Tables I and II. Compared with their respective parental cell lines, the increase of resistance against DOX in MCF-7/DOX cells was ~469-fold, whilst resistance against HAR in HL-60/HAR cells was 240-fold. The IC₅₀ values in MCF-7/DOX cells divided by those in MCF-7 cells. DOX, doxorubicin.

### Table I. IC₅₀ values of various drugs for MCF-7/DOX and sensitive MCF-7 cells.

| Drug                        | IC₅₀ for MCF-7 (µM) | IC₅₀ for MCF-7/DOX (µM) | Resistant folds |
|-----------------------------|---------------------|-------------------------|-----------------|
| DOX                         | 0.23±0.02           | 108.00±2.94             | 469.6           |
| Vincristine                 | 0.03±0.01           | 5.92±1.63               | 196.6           |
| cis-diamminedichloroplatinum| 13.10±0.30          | 4.94±1.62               | 0.4             |
| Oleanolic acid              | 83.40±5.61          | 79.13±3.71              | 0.9             |

The inhibitory rate of cell survival was determined with Cell Counting Kit-8 assay. The results are represented as the mean ± SD from three separate experiments. The resistant folds are obtained from IC₅₀ values in MCF-7/DOX cells divided by those in MCF-7 cells. DOX, doxorubicin.
accumulated in sensitive MCF-7 and HL-60 cells, more than that observed in MCF-7/DOX and HL-60/HAR cells.

There was a notably different result in the cell survival rates of OA treatment groups between MCF-7/DOX and HL-60/HAR cells. MCF-7/DOX cells exhibited little difference in sensitivity to OA compared with that in their parental MCF-7 cells (Table I). However, HL-60/HAR cells were four-fold more sensitive to OA compared with that in their parental HL-60 cells (Table II). Based on this finding, HL-60/HAR cells were treated with lower concentrations of OA (2, 5, 10, 20 and 40 µM) for subsequent experiments. It should be noted that additional cell proliferation methods, such as BrdU, should also be used for precisely measuring proliferation of drug resistant cells.

Effect of CAV-1 knockdown on OA sensitivity in MCF-7/DOX cells.

Overexpression of CAV-1 in HL-60 cells increases their sensitivity to OA, as demonstrated in a previous study (17). In the present study, upregulation of CAV-1 was found in MCF-7/DOX and HL-60/HAR both cell lines as determined using flow cytometry. One of representative results from three independent experiments is presented. ABCB1, ATP-binding cassette subfamily B member 1; CAV-1, caveolin-1; Rho 123, rhodamine 123; DOX, doxorubicin; HAR, harringtonine.

Table II. IC_{50} values of various drugs for the inhibitions of HL-60/HAR and sensitive HL-60 cells.

| Drug       | IC_{50} for HL-60 (µM) | IC_{50} for HL-60/HAR (µM) | Resistant folds |
|------------|------------------------|----------------------------|-----------------|
| HAR        | 0.01±0.01              | 2.40±0.40                  | 240             |
| Doxorubicin| 0.06±0.01              | 0.92±0.23                  | 15              |
| Vincristine| 0.008±0.001            | 0.62±0.05                  | 750             |
| Imatinib   | 21.84±2.62             | 18.31±0.73                 | 0.8             |
| Oleanolic acid | 82.24±2.22          | 18.50±6.34                 | 0.2             |

The inhibitory rate of cell survival was determined using a Cell Counting Kit-8 assay. The results are represented as the mean ± SD from three separate experiments. Resistant folds are obtained from IC_{50} values in HL-60/HAR cells divided by those in HL-60 cells. HAR, harringtonine.
CAV-1 siRNA-transfected MCF-7/DOX cells after the cells were treated with 80 and 120 µM OA for 48 h (Fig. 2B).

\textbf{G}_1 \text{ phase cell cycle arrest after OA treatment in both drug resistant cell lines.} Cell cycle distribution was analyzed using flow cytometry after the cells were treated with different concentrations of OA for 24 h. The results demonstrated that the percentage of cells at \text{G}_1 \text{ phase increased a small amount with increasing concentrations of OA in sensitive MCF-7 cells (Fig. 2A). For example, the \text{G}_1 \text{ percentage was 64.2\% in the control group and was 68.7\% in the 100 \mu M OA-treatment group. However, the \text{G}_1 \text{ percentage in MCF-7/DOX cells treated with the same concentration of OA was 93.5\%, indicating an increased percentage of \text{G}_1 \text{ phase cells compared with that in the sensitive cells (Fig. 3A). In addition, the percentage of \text{G}_1 \text{ phase cells was 53.3\% in the control group and 53.4\% after sensitive HL-60 cells were treated with 80 \mu M OA (Fig. 3B). OA concentrations of 5, 10 and 20 \mu M were used for cell cycle analysis as HL-60/HAR cells tended to be more sensitive to OA, compared with sensitive HL-60 cells, as shown in a preliminary cell survival experiment (Table II). The percentage of \text{G}_1 \text{ phase cells was 82.1\% in the 20 \mu M OA-treatment group, whilst no notable changes in the percentage of \text{G}_1 \text{ phase cells were detected with high concentrations of OA treatment (80 \mu M) in sensitive HL-60 cells compared with that in the control cells (Fig. 3B). These results suggested that HL-60/HAR cells were more sensitive to OA in comparison with their corresponding sensitive parental HL-60 cells.}

\textbf{Induction of apoptosis by OA in MCF-7 cells.} The apoptotic rate of cells was next detected using Annexin V/PI-staining after MCF-7 cells were treated with different concentrations of OA for 48 h. The apoptotic rates of MCF-7 cells treated with OA were gradually increased in a concentration-dependent manner (Fig. 4A and B). The apoptosis rate was 13.4\% in sensitive MCF-7 cells after exposure to 100 \mu M OA. However, the apoptotic rate in MCF-7/DOX cells was 22.7\% after OA treatment at the same concentration, indicating enhanced apoptosis compared with that observed in their corresponding parental sensitive cells. Changes in apoptosis-related protein expression were detected by western blotting. The cleavage of PARP-1 is a biomarker of apoptosis that is used as an indicator of apoptotic occurrence (23). The cleavage fragments of PARP-1 and activated CASP-3 were detected after sensitive MCF-7 cells and MCF-7/DOX cells were treated with increasing concentrations of OA up to 100 \mu M for 48 h (Fig. 4C),
where an increased number of cleaved fragments of PARP-1 and CASP-3 were observed in MCF-7/DOX cells treated with the same concentration (100 µM), compared with sensitive MCF-7 cells. The cleaved fragments were also observed at lower concentrations of OA treatment in MCF-7/DOX cells (Fig. 4C). The results from the apoptosis assay further indicated that MCF-7/DOX cells were more sensitive to OA.

**Effect of OA treatment on apoptosis in HL-60/HAR cells.** As detected using an Annexin V/PI staining assay, the apoptotic rate of sensitive HL-60 cells was 35.8% after exposure to 80 µM OA, whilst the apoptotic rate was 30.4% in 40 µM OA-treated HL-60/HAR cells (Fig. 5A and B), suggesting that HL-60/HAR cells were more sensitive to OA compared with their parental HL-60 cells. The pattern of staining of the apoptotic markers differed between the resistant and sensitive cell lines. Cleaved fragments from CASP-3 and PARP-1 were observed in sensitive cells after exposure to 80 µM OA. However, no cleavage of PARP-1 was detected in HL-60/HAR cells (Fig. 5C). In addition, lower expression levels of CASP-3 were observed after treatment with the highest concentration of OA (40 µM), but no cleavage of CASP-3 was identified. These results suggested that OA induces a non-classical apoptosis pathway or other cell death pathways in resistant HL-60 cells.
Rho 123 accumulation after exposure to OA in both resistant cell lines. A slight accumulation of Rho 123 was observed after the MCF-7/DOX cells were treated with OA for 1 h, but this was not concentration-dependent (Fig. 6A). Similarly, a slight Rho 123 accumulation was detected in HL-60/HAR cells after OA treatment for 1 h (Fig. 6B). These results indicated that OA does not directly bind with ABCB1.

Reduction in ABCB1 protein expression by OA in both resistant cells. ABCB1 mainly mediates multidrug resistance in tumor cells (12). Therefore, it was examined whether OA influences the protein expression levels of ABCB1 in the resistant cell lines. ABCB1 protein expression levels in both resistant cell lines were significantly decreased with increasing OA concentrations (Fig. 7). These effects occurred at lower concentrations of OA treatment in HL-60/HAR cells, when compared with those in MCF-7/DOX cells (Fig. 7A and C). These findings were consistent with aforementioned results, suggesting that HL-60/HAR cells were more sensitive to OA compared with MCF-7/DOX cells.

Discussion
The present study characterized the effects of OA on the cell viability and apoptosis of multidrug-resistant tumor cell lines.
The MCF-7/DOX and HL-60/HAR cell lines have multiple drug resistance (Tables I and II). This is consistent with findings from previous studies on these two drug-resistant cell lines (19,22). To the best of our knowledge, the present study was the first to demonstrate that OA can arrest the cell cycle at the G₁ phase in drug-resistant cells. Although OA cannot enhance Rho 123 accumulation in drug-resistant cells, it can decrease ABCB1 protein expression in a concentration-dependent manner. These findings could be valuable for the clinic application of OA in tumor therapy. Moreover, some types of drug-resistant tumor cells in particular may be more suitable for OA treatment, such as leukemia cells.

Accumulating evidence has revealed that OA can arrest the cell cycle at the G₁ phase in a variety of tumor cell types, including prostate cancer PC-3 cells (3) and gallbladder cancer cells (11). In the present study, G₁ arrest was induced by OA treatment in both drug-resistant cell lines (Fig. 3). Furthermore, the percentage of cells in G₁ phase was increased after exposure to OA in both drug-resistant cell lines. (A) MCF-7/DOX cells treated with different concentrations of OA were analyzed for G₁ phase by flow cytometry. (B) HL-60/HAR cells treated with different concentrations of OA were also analyzed for G₁ phase by flow cytometry.
to low concentrations of OA in resistant HL-60/HAR cells, suggesting that there is a novel mechanism of the regulation of the G1 phase of the cell cycle in drug-resistant cells. Induction of autophagy by OA in lung cancer A549 cells and breast cancer MCF-7 cells has been reported in previous studies (5,24), where G1 phase cell cycle arrest frequently occurs during autophagy (25). Therefore, it was hypothesized that the autophagic process may differ in the drug-resistant cells compared with their parent cell lines. However, further investigation is required to test this hypothesis.

The present results suggested that OA was not a substrate of ABCB1, which is consistent with previous studies (15,26), which observed that OA affected MRP1 function but not ABCB1. The OA derivative, methyl 3,11-dioxoolean-12-en-28-olate, can target ABCB1 (16), suggesting that the chemical structure of OA prevents its interaction with ABCB1 protein. Since the present study only determined ABCB1 function after OA treatment for 2.5 h and detected Rho 123 accumulation by flow cytometry, limitations exist of regarding this method, including the specificity of Rho 123, as Rho 123 activity may not be representative of ABCB1 levels. Attention should be paid to the difference between Rho 123 accumulation and OA-induced reductions in ABCB1 protein expression.

To the best of our knowledge, the present study was the first to demonstrate that OA can decrease ABCB1 protein levels (Fig. 7). However, the signaling pathway mechanism for this reduction in ABCB1 was not investigated in the present study. It may possibly involve the mTOR pathway since OA has been previously reported to inhibit it’s signaling (8,17). Further investigations currently underway to test this hypothesis.

The direct targets of OA in tumor cells remain unknown. OA can reportedly promote the dimerization of inducible nitric oxide synthase, thereby inhibiting hepatocellular carcinoma growth (27). It also been reported that transfection of CAV-1 into HL-60 cells can enhance their sensitivity to OA (17). However, the present results indicated that CAV-1 knockdown did not influence the survival of MCF-7/DOX cells after OA treatment, suggesting that CAV-1 serves an indirect role in the mechanism of OA action. In the present study, it has not determined whether OA treatment can increase CAV-1 expression. OA derivative, 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid, can increase CAV-1 expression in colon cancer cells (28). Further studies are needed to demonstrate if overexpression of CAV-1 serves a role in MCF-7/DOX cell lines. The human leukemia HL-60 cell line lacks the TP53 gene (29), where introduction of the wild-type TP53 gene potentiates its susceptibility to chemotherapy (30). It was speculated that CAV-1 may function similarly during OA-induced apoptosis in sensitive HL-60 cells (17). OA has a selective action on melanoma cells, but mediated no cytotoxicity towards normal stem cells (31). In addition, the present study demonstrated that HL-60/HAR cells are more sensitive to OA compared with parental HL-60. These findings suggest that the molecular target of OA should be further investigated using drug-resistant HL-60 cells.

In conclusion, OA treatment can arrest the cell cycle at the G1 phase in drug-resistant tumor cells and efficiently reduce ABCB1 protein expression, indicating its potential in reversing drug resistance. The present findings suggested that it may be possible to effectively target certain types of cancer using OA, such as leukemia, in the clinical setting. In recent years, numerous dietary components have been demonstrated to enhance the efficacy of cancer therapy, such as in the treatment of lymphoma (32). The present findings indicated the potential applicability of OA, which has low toxicity and few adverse effects, for tumor prevention and therapy.

Acknowledgements

Not applicable.

Funding

The present study was supported by Heilongjiang Province North Medicine and Functional Food Project, Natural Scientific Foundation of China (grant no. 31471150), The Team of Jiamusi University Biology (grant no. jdxktd2019003), Jiamusi University President Innovation and Entrepreneurship Fund Project (grant no. XYZF2018-36), Jiamusi University Graduate Science and Technology Innovation Project (grant no. LZZ2015_009) and Jiamusi University Science and Technology School-level General Project (grant no. 13Z1201529).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

QH, PZ and JiaW conceived and designed the study. DW, JinW, JZ, XY, JP and LL performed the experiments and analyzed the data. DW and QH authenticated the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Žiberna L, Šamec D, Mocan A, Nabavi SF, Bishayee A, Farooqui AA, Sureda A and Nabavi SM: Oleanolic acid alters multiple cell signaling pathways: Implication in cancer prevention and therapy. Int J Mol Sci 18: 643, 2017.
2. Ayelos TB, Matumba MG and Mukwevho E: Oleanolic acid and its derivatives: Biological activities and therapeutic potential in chronic diseases. Molecules 22: 1915, 2017.
3. Liu J, Zheng L, Wu N, Ma L, Zhong J, Liu G and Lin X: Oleanolic acid induces metabolic adaptation in cancer cells by activating the AMP-activated protein kinase pathway. J Agric Food Chem 62: 5528-5537, 2014.
4. Fontana G, Bruno M, Notarbartolo M, Labbozzetta M, Poma P, Spinella A and Rosselli S: Cytotoxicity of oleanolic and ursolic acid derivatives toward hepatocellular carcinoma and evaluation of NF-κB involvement. Bioorg Chem 90: 103054, 2019.
5. Liu J, Zheng L, Zhong J, Wu N, Liu G and Lin X: Oleanolic acid induces protective autophagy in cancer cells through the JNK and mTOR pathways. Oncol Rep 32: 567-572, 2014.
6. Shi Y, Song Q, Hu D, Zhuang X, Yu S and Teng D: Oleanolic acid induced autophagic cell death in hepatocellular carcinoma cells via PI3K/Akt/mTOR and ROS-dependent pathway. Korean J Physiol Pharmacol 20: 237-243, 2016.
7. Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z and Hai C: Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial dependent apoptosis. Carcinogenesis 34: 1323-1330, 2013.
8. Mu DW, Guo HQ, Zhou GB, Li JY and Su B: Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling. Int J Clin Exp Pathol 8: 13864-13870, 2015.
9. Xu Y, Shu B, Tian Y, Wang G, Wang Y, Wang J and Dong Y: Oleanolic acid induces osteosarcoma cell apoptosis by inhibition of Notch signaling. Mol Carcinog 57: 896-902, 2018.
10. Potočnjak I, Šimić L, Vukelić I and Domitrović R: Oleanolic acid attenuates cisplatin-induced nephrotoxicity in mice and chemosensitizes human cervical cancer cells to cisplatin cytotoxicity. Food Chem Toxicol 132: 11067, 2019.
11. Li HF, Wang XA, Xiang SS, Hu YP, Jiang L, Shu YJ, Li ML, Wu XS, Zhang F, Ye YY, et al: Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells. Drug Des Devel Ther 9: 3017-3030, 2015.
12. Robey RW, Pluchino KM, Hall MD, Bates SE and Gottesman MM: Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 18: 452-464, 2018.
13. Dastvan R, Mishra S, Peskova YB, Nakamoto RK and Mchaourab HS: Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors. Science 364: 689-692, 2019.
14. Alam A, Kowal J, Broude E, Roninson I and Locher KP: Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science 363: 753-756, 2019.
15. Villar VH, Vogler O, Barceló F, Gómez-Florit M, Martínez-Serra J, ObraD-Heriva A, Martín-Broto J, Ruiz-Gutiérrez V and Alemany R: Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein. J Nutr Biochem 25: 429-438, 2014.
16. Paszela A, Rubiś B, Bednarczyk-Cywnar B, Zaprutko L, Kaczmarek M, Hofmann J and Rybczyńska M: Oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1. Pharmacol Rep 63: 1500-1517, 2011.
17. Ma W, Wang DD, Li L, Feng YK, Gu HM, Zhu GM, Piao JH, Yang Y, Gao X and Zhang PX: Caveolin-1 plays a key role in the oleanolic acid-induced apoptosis of HL-60 cells. Oncol Rep 32: 293-301, 2014.
18. Chen J, Chen Y and He Q: Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1. Int J Oncol 41: 2245-2252, 2012.
19. He Q, Zhou W, Ji L, Zhang H, He N and Xue S: Characteristics of harringtonine-resistant human leukemia HL60 cell. Zhongguo Yao Li Xue Bao 17: 463-467, 1996.
20. Zhang J, Chen Y and He Q: Distinct characteristics of Dasatinib-induced pyroptosis in gsdamerin E-expressing human lung cancer A549 cells and neuroblastoma SH-SY5Y cells. Oncol Lett 20: 145-154, 2020.
21. Nasim F, Schmid D, Szakács G, Sobhali A, Sittte HH, Chiba P and Stockner T: Active transport of rhodamine 123 by the human multidrug transporter P-glycoprotein involves two independent outer gates. Pharmacol Res Perspect 8: e00572, 2020.
22. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH and Goldsmith ME: Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141-5148, 1987.
23. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotheraphy-induced apoptosis. Cancer Res 53: 3976-3985, 1993.
24. Gao L, Wang Y, Xu Z, Li X, Wu J, Liu S, Chu P, Sun Z, Sun B, Lin Y, et al: SZC017, a novel oleanolic acid derivative, induces apoptosis and autophagy in human breast cancer cells. Apoptosis 20: 1636-1650, 2015.
25. Tasdemir E, Mavri MC, Tajeddine N, Vitale I, Criollo A, Vicencio JM, Hickman JA, Geneste O and Kroemer G: Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. Cell Cycle 6: 2263-2267, 2007.
26. Braga F, Ayres-Saraiva D, Gattass CR and Capella MA: Oleanolic acid inhibits the activity of the multidrug resistance protein ABCG1 (MRP1) but not of the ABCB1 (P-glycoprotein): Possible use in cancer chemotherapy. Cancer Lett 248: 147-152, 2007.
27. Wang H, Zhong W, Zhao J, Zhang H, Zhang Q, Liang Y, Chen S, Liu H, Zong S, Tian Y, et al: Oleanolic acid inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by promoting iNOS dimerization. Mol Cancer Ther 18: 62-74, 2019.
28. Chintharlapalli S, Papineni S, Konopleva M, Andreeff M, Samudio I and Safe S: 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 68: 119-128, 2005.
29. Wolf D and Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82: 790-794, 1985.
30. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schöntahl AH, Mannio DJ, Hochhauser D, Bertino JR, et al: Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 4: 1315-1322, 1998.
31. Opreat C, Ivan A, Bojin F, Cristea M, Soica C, Drăghia L, Caunii A, Paunescu V and Tatu C: Selective in vitro anti-melanoma activity of ursolic and oleanolic acids. Toxicol Mech Methods 28: 148-156, 2018.
32. Kanarek N, Petrova B and Sabatini DM: Dietary modifications affect melanoma activity of ursolic and oleanolic acids. Toxicol Mech Methods 28: 148‑156, 2018.
33. Kaczmarek M, Hofmann J and Rybczyńska M: Oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1. Pharmacol Rep 63: 1500-1517, 2011.
34. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.